![Gabriel Brooks](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Gabriel Brooks
Directeur Technique/Scientifique/R&D chez
SOLID BIOSCIENCES INC.
Fortune : 857 084 $ au 31/08/2026
Profil
Gabriel Brooks is Chief Medical Officer at Solid Biosciences, Inc. since 2023.
Formerly, Dr. Brooks was Vice President-Research & Development at 4D Molecular Therapeutics, Inc. from 2018 to 2020.
Education includes undergraduate studies at Carnegie Mellon University, a doctorate from Cornell University, and graduate studies at the University of California.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2026 | 89 466 ( 0,08% ) | 857 084 $ | 31/08/2026 |
Postes actifs de Gabriel Brooks
| Sociétés | Poste | Début |
|---|---|---|
| SOLID BIOSCIENCES INC. | Directeur Technique/Scientifique/R&D | 02/10/2023 |
Anciens postes connus de Gabriel Brooks
| Sociétés | Poste | Fin |
|---|---|---|
| 4D MOLECULAR THERAPEUTICS, INC. | Corporate Officer/Principal | 01/09/2020 |
Formation de Gabriel Brooks
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
31
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Carnegie Mellon University
 Carnegie Mellon University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California
 University of California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
4D Molecular Therapeutics, Inc.
 4D Molecular Therapeutics, Inc. BiotechnologyHealth Technology Designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions | Health Technology |
Solid Biosciences, Inc.
 Solid Biosciences, Inc. BiotechnologyHealth Technology Operates as a pharmaceutical company that develops treatments through gene therapy for patients with duchenne disease | Health Technology |
